CLINICAL TRIALS PROFILE FOR CAMPTOTHECIN
✉ Email this page to a colleague
Clinical Trials for Camptothecin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00001427 ↗ | A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin | Completed | National Cancer Institute (NCI) | Phase 2 | The objectives of this study are to determine the response rate to 9-AC in patients with advanced ovarian cancer who have recurrent disease after paclitaxel- and cisplatin-based chemotherapy regimens. |
| NCT00001495 ↗ | A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | This study examines a 96 hour infusion schedule of irinotecan alternating with 72 hour drug-free intervals in patients with solid tumors in order to determine the maximum tolerated dose of this regimen. |
| NCT00002635 ↗ | Aminocamptothecin in Treating Patients With T-cell Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Camptothecin
Condition Name
Clinical Trial Locations for Camptothecin
Trials by Country
Clinical Trial Progress for Camptothecin
Clinical Trial Phase
Clinical Trial Sponsors for Camptothecin
Sponsor Name
